Idera, Merck deal

IDP granted MRK an exclusive worldwide license to develop and commercialize IDP's preclinical toll-like receptor (TLR) agonists for

Read the full 182 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE